Globenewswire·2025-10-02 20:43Core Points - XOMA Royalty Corporation has extended its tender offer to purchase all outstanding shares of LAVA Therapeutics N.V. until October 17, 2025, with the acquisition expected to close in Q4 2025 [1][2] Group 1: Tender Offer Details - The tender offer includes a cash amount and a non-transferable contingent value right (CVR) per share, entitling shareholders to 75% of net proceeds from LAVA's partnered assets and any out-licensed or sold unpartnered programs [1] - LAVA shareholders who have already tendered their shares do not need to take further action due to the extension of the offer [3] - The closing of the offer is contingent upon the tender of at least 80% of LAVA's outstanding shares, adoption of certain resolutions by LAVA's shareholders, and other customary closing conditions [4] Group 2: Company Background - XOMA Royalty is a biotechnology royalty aggregator that acquires future economic rights associated with therapeutic candidates licensed to pharmaceutical companies, providing non-dilutive funding to sellers [5] - LAVA Therapeutics is a biopharmaceutical company focused on developing bispecific gamma delta T cell engagers using its proprietary Gammabody® platform, with partnerships with Johnson & Johnson and Pfizer [6][7]